MBOT vs MDT

Microbot Medical remains an intriguing high-risk, high-reward play in the rapidly expanding robotic endovascular surgery market, buoyed by its FDA-cleared LIBERTY system and proprietary technology. While the previous $15 million public offering temporarily mitigated immediate financial fragility, providing 7-8 months of runway as of late January 2026, approximately 53 days have passed. Assuming a ...

Medtronic PLC (MDT) remains a global leader in medical technology with a robust portfolio, strong distribution, and a wide economic moat. Its strengths lie in stability, consistent innovation, and significant free cash flow generation, making it a reliable large-cap investment. However, its mature industry positioning and inherent large size fundamentally limit its potential for 10x growth within ...